In the first episode of this three-part series focused on the presentations and findings from the ESMO Congress 2024, our hosts focus on mCSPC prostate cancer treatment advancements, including lutetium PSMA, darolutamide and much more. The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related